不同剂量FLAG方案治疗难治性急性髓系白血病  

Different Dosages of FLAG Regimen in Treatment of Refractory Acute Myeloid Leukemia(AML)

作　　者：娄晔[1] 詹立辉[2] 李娜嘉[1] 李雪松[1] 樊华[2] 

机构地区：[1]大庆油田总医院,黑龙江大庆163000 [2]中国医科大学附属第一医院,中国沈阳110000

出　　处：《黑龙江医学》2008年第10期760-761,共2页Heilongjiang Medical Journal

摘　　要：目的研究标准和改良FALG方案治疗急性难治性髓系白血病（AML）的临床效果。方法选择中国医科大学附属一院血液科内科2005-06～2007-11间,收治的27例难治性AML患者。分为两组：标准剂量组15例,具体方案为氟达拉滨（Flu）50 mg/（m2·d）^-1,30 min内静滴,连用5 d;Ara-C 1 000 mg/（m2·d）^-1,连用5 d,化疗第1～5 d,应用粒细胞集落刺激因子300μg/d。改良组12例Ara-c 500mg/（m2·d）^-1,连用5 d,其余药物和标准剂量组相同。结果标准组的1个疗程完全缓解（CR）率较改良组高,两组比较有统计学意义（P〈0.05）;两组间并发症发生率无明显差异,无统计学意义（P〉0.05）。结论标准FLAG方案与改良FLAG方案治疗难治性AML相比较,完全CR率高,但感染等并发症未见明显升高。Objective To investigate the clinic effects of standard and improved FLAG regimen in treatment of refractory and relapsed acute myeloid leukemia （AML）. Methods 15 patients with refractory acute myeloid leukemia divided two sets, in blood medical department of China Medical University from June, 2005 to November, 2007.15 patients in standard dosage cytosine ambinoside（Ara- c） group were treated with fludarabine（Plu） 50 mg/（m2·d）^-1, 30 rain, intravenous drip, d1 - d5 ; Am - C 1 000 mg/（m2·d）^-1, d1 - d5. granulocyte colony - stimulating factor 300 μg/d, dl - d5; 12 patients in low dosage Am- C group：Am- c 500 mg/（m2·d）^-1, d1 - d5,the rest medicine is the same as the dstandard dosage group. Results The complete remission （CR） rate of dstandard dosage Am- C group is higher than low dosage group （ P 〈 0.05） there is no statistically significant with complication such as infection. Conclusion The, improved FLAG regimen in treatment of refractory and relap seal acute myeloid leukemia （AML）, which is not significantly lessen the complication of chemotherapy such as infection and bone marrow depression, but the complete remission （CR） rate is significantly lower than standard dosage.

关 键 词：氟达拉滨 阿糖胞苷 急性髓系白血病 难治性 

分 类 号：R979.1[医药卫生—药品] R733.71[医药卫生—药学]